home / stock / spro / spro quote
Last: | $1.41 |
---|---|
Change Percent: | 0.69% |
Open: | $1.43 |
Close: | $1.41 |
High: | $1.4396 |
Low: | $1.4 |
Volume: | 43,369 |
Last Trade Date Time: | 07/30/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.41 | $1.43 | $1.41 | $1.4396 | $1.4 | 43,369 | 07-30-2024 |
$1.44 | $1.45 | $1.44 | $1.45 | $1.41 | 50,449 | 07-29-2024 |
$1.435 | $1.41 | $1.435 | $1.44 | $1.4 | 38,566 | 07-26-2024 |
$1.415 | $1.38 | $1.415 | $1.47 | $1.37 | 47,343 | 07-25-2024 |
$1.38 | $1.38 | $1.38 | $1.4 | $1.37 | 38,682 | 07-24-2024 |
$1.38 | $1.39 | $1.38 | $1.42 | $1.37 | 64,071 | 07-23-2024 |
$1.395 | $1.42 | $1.395 | $1.42 | $1.39 | 47,788 | 07-22-2024 |
$1.4 | $1.4055 | $1.4 | $1.42 | $1.39 | 42,662 | 07-19-2024 |
$1.42 | $1.48 | $1.42 | $1.49 | $1.4 | 107,446 | 07-18-2024 |
$1.48 | $1.5 | $1.48 | $1.51 | $1.45 | 121,754 | 07-17-2024 |
$1.5 | $1.46 | $1.5 | $1.53 | $1.455 | 248,761 | 07-16-2024 |
$1.445 | $1.42 | $1.445 | $1.45 | $1.41 | 101,296 | 07-15-2024 |
$1.415 | $1.41 | $1.415 | $1.42 | $1.38 | 135,217 | 07-12-2024 |
$1.385 | $1.35 | $1.385 | $1.45 | $1.35 | 64,297 | 07-11-2024 |
$1.36 | $1.36 | $1.36 | $1.41 | $1.31 | 306,288 | 07-10-2024 |
$1.355 | $1.29 | $1.355 | $1.38 | $1.2701 | 215,782 | 07-09-2024 |
$1.27 | $1.31 | $1.27 | $1.3299 | $1.27 | 72,537 | 07-08-2024 |
$1.31 | $1.3 | $1.31 | $1.3117 | $1.29 | 60,886 | 07-05-2024 |
$1.325 | $1.32 | $1.325 | $1.33 | $1.3 | 20,910 | 07-04-2024 |
$1.325 | $1.32 | $1.325 | $1.33 | $1.3 | 20,910 | 07-03-2024 |
News, Short Squeeze, Breakout and More Instantly...
Spero Therapeutics Inc. Company Name:
SPRO Stock Symbol:
NASDAQ Market:
Spero Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced th...
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced t...
CAMBRIDGE, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced tha...